Mankind Pharma is setting up a dedicated unit for manufacturing of ‘dydrogesterone’ in Udaipur, Rajasthan with an investment of about Rs 250-Rs 300 crore.
The plant will manufacture dydrogesterone key starting materials, active pharmaceutical ingredients (API) and formulations. It is expected to begin operations by September-October 2023.
The complex hormone is widely used in treating infertility and preventing miscarriages.
Once the pharmaceutical company achieves the scale and vertical integration at the facility, it will work on rationalising the price, and further intends to take the product delivery beyond India.
The New Delhi-based company had launched dydrogesterone in 2019. Its research and development (R&D) unit is engaged in drug development.